To validate the efficacious use of the TAK1 inhibitor in patients affected by the recurrence of glioblastoma, we performed a Western blot analysis in glioblastoma TMZ treated tissue samples and compared this with brain tissue from healthy patients. Here, MAP3K7 is linked to glioblastoma.